ALZH: Alzheon, Inc. - Summary | Jitta

Alzheon, Inc.

NASDAQ:ALZH

Notice
Stock data is unavailable or the company’s delisted.
Price
n/a
Loss Chance
58.4%
0.56JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Related
Sorry, the data is not yet available for this stock.
Jitta Factors
Growth Opportunity (5)
Recent Business Performance (6)
Financial Strength (12)
Return to Shareholders (12)
Competitive Advantage (8)
Jitta Signs
SG&A to SalesDecreasing Every Year
Cash Conversion CycleLess than 30 days
Recent IPOLess than 3 years
Recent Business PerformanceEarning decline 34.89% in the last quarter (yoy)
SG&A to SalesIncreasing Every Year
Key Stats
Jitta Score
Jitta Line
0.56
100.00%
2.22
281.50%
2.22
281.50%
COMPANY DESCRIPTION
Alzheon, Inc. operates as a clinical stage biopharmaceutical company in the United States and internationally. Its products include ALZ-801, an orally administered inhibitor of beta amyloid misfolding that helps in treating Alzheimer’s disease and other neurological disorders. Its preclinical candidate compound includes ALZ-1903, a chemical entity and potent inhibitor of beta amyloid misfolding. Alzheon, Inc. has a collaboration and license agreement with the Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences to develop a clinical assay to measure neurotoxic beta amyloid oligomers in human cerebrospinal fluid. The company was founded in 2013 and is based in Framingham, Massachusetts.